OCT 27·SEC EDGARLow
Manieu Alexandre Weinstein purchased $1.3M of PLUR (indirect holdings)
Manieu Alexandre Weinstein purchased 833,334 indirectly-held shares of Pluri Inc. (PLUR) at $1.50 ($1.25M total) on 2026-10-23.
StockNASDAQ · US · USDHealthcare · Biotechnology
$PLUR
Pluri Inc.
Price · $PLURvia TradingView
AI sentiment · 7d3 articles
- Bullish
- 2
- Neutral
- 1
- Bearish
- 0
Insider · 30dAll trades →
- Buys
- $1.3M 1 txs
- Sells
- — 0 txs
Manieu Alexandre Weinstein1× · $1.3M
10b5-1 share of filings0%
Top stories · $PLURMore →
OCT 26·insidermonkey.com
Pluri and ZEO ScientifiX Partner to Expand U.S. Manufacturing and Commercial Platform
Pluri Inc. (PLUR) and ZEO ScientifiX (ZEOX) have partnered to expand their U.S. manufacturing and commercial platform for regenerative medicine. The deal combines Pluri's cell technology and clinical experience with ZEO's biologics manufacturing and sales network. Pluri will own 50% of ZEO post-closing, with the transaction expected to close in Q4 2026.
OCT 20·tradingview.com
Pluri Raises $1.25 Million in Private Placement to Largest Holder, Issues Matching Warrant
Pluri Inc. (PLUR) raised $1.25M in a private placement with its largest shareholder, Chutzpah Holdings. The deal includes 833,334 shares at $1.50 each and a warrant for up to 833,334 shares at $1.65, exercisable after 6 months. The funds aim to bolster liquidity.
PLUR sentiment & insider activity
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning PLUR (Pluri Inc.). Coverage has skewed bullish: 2 bullish, 1 neutral, and 0 bearish.
Recent PLUR coverage spans corporate actions, financial news and insider activity.
In the last 30 days, PLUR insiders filed 1 SEC Form 4 transaction — 1 purchase ($1.3M) and no sales. The most active reporter was Manieu Alexandre Weinstein with 1 filing.
What's driving PLUR
Insider purchase suggests confidence in Pluri, but the transaction size is modest relative to market cap.
Potential upside as the partnership expands Pluri's commercial platform, but share issuance may cause dilution.
The capital raise provides immediate liquidity and a future equity upside via the warrant, which may modestly support the share price.
The financing dilutes existing shareholders and adds modest cash, likely creating slight downward pressure on the stock.
The modest capital raise provides short‑term liquidity for corporate development but is unlikely to move the stock significantly.
AlphAI scores every news story that mentions PLUR with an AI model for sentiment and relevance, and aggregates insider trades from Pluri Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $PLUR
Score
Manieu Alexandre Weinstein purchased $1.3M of PLUR (indirect holdings)
Manieu Alexandre Weinstein purchased 833,334 indirectly-held shares of Pluri Inc. (PLUR) at $1.50 ($1.25M total) on 2026-10-23.
1 min read
Pluri and ZEO ScientifiX Partner to Expand U.S. Manufacturing and Commercial Platform
Pluri Inc. (PLUR) and ZEO ScientifiX (ZEOX) have partnered to expand their U.S. manufacturing and commercial platform for regenerative medicine. The deal combines Pluri's cell technology and clinical experience with ZEO's biologics manufacturing and sales network. Pluri will own 50% of ZEO post-closing, with the transaction expected to close in Q4 2026.
3 min read
Pluri Raises $1.25 Million in Private Placement to Largest Holder, Issues Matching Warrant
Pluri Inc. (PLUR) raised $1.25M in a private placement with its largest shareholder, Chutzpah Holdings. The deal includes 833,334 shares at $1.50 each and a warrant for up to 833,334 shares at $1.65, exercisable after 6 months. The funds aim to bolster liquidity.
1 min readPluri Inc. (PLUR): Entry into a Material Definitive Agreement
Pluri Inc. (PLUR) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. As previously disclosed, on June 14, 2026, Pluri Inc. (the “Company”) entered into an advance subscription agreement with Chutzpah Holdings LP (the “Purchaser”), a limited partnership beneficially owned by Mr. Alexandre Weinst
1 min readPluri Inc. (PLUR): Entry into a Material Definitive Agreement
Pluri Inc. (PLUR) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On August 26, 2026, Pluri Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with a certain institutional investor (the “Purchaser”) pursuant to which the Company agreed to issue and s
1 min readEver After Foods Ltd., an indirect majority-owned subsidiary of Pluri Inc., entered into a share purchase agreement with Fishway BV and the holders of…
Pluri Inc. (PLUR) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On August 12, 2026, Ever After Foods Ltd. (“EAF”), an indirect majority-owned subsidiary of Pluri Inc. (the “Company”), entered into a share purchase agreement (the “Share Purchase Agreement”) with Fishway BV (“Fishway”) and the holders of certain securiti
2 min read
Pluri Chairman Alejandro Weinstein’s Cumulative Investment Exceeds $17 Million, Ownership Surpasses 30%
Pluri Inc. (PLUR) said Chairman Alejandro Weinstein invested over $17 million in the past year, including a $1.25 million advance investment in June 2026 under an Advance Subscription Agreement. The company said he now owns more than 30% of issued shares. Pluri linked the purchases to its shift toward U.S. commercialization and longevity focus.
3 min readPluri Inc. (PLUR): Entry into a Material Definitive Agreement
Pluri Inc. (PLUR) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. false 0001158780 0001158780 2026-06-15 2026-06-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report
4 min read
Plurilock Security (CVE:PLUR) Reaches New 1
Plurilock Security Inc. (CVE:PLUR) hit a new 52-week low in Thursday trading, falling to C$0.11 and last trading at C$0.10 versus a prior close of C$0.10. Volume was 16,024 shares. The stock’s market cap is C$7.96 million, with 50-day and 200-day moving averages of C$0.11 and C$0.16, respectively.
1 min read
New cell-free therapy for fibrotic diseases clears key manufacturing step
Pluri (PLUR) and Remedy Cell have expanded their manufacturing collaboration after PluriCDMO successfully implemented Remedy Cell's proprietary process, conducted GMP training, and produced clinical-grade batches for a planned Phase 1b trial. This milestone marks significant progress for Remedy Cell's cell-free therapeutics for fibrotic conditions and reinforces PluriCDMO's role as a key manufacturing partner for complex biologics. The expanded agreement will see PluriCDMO continue to support Remedy Cell's clinical and pre-commercial programs.
2 min read